Compare · NTRA vs SPNE
NTRA vs SPNE
Side-by-side comparison of Natera Inc. (NTRA) and SeaSpine Holdings Corporation (SPNE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and SPNE operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $30.84B, about 74.3x SPNE ($415.1M).
- NTRA has hit the wire 16 times in the past 4 weeks while SPNE has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 5 for SPNE).
- Company
- Natera Inc.
- SeaSpine Holdings Corporation
- Price
- $215.22-0.04%
- $9.52+8.18%
- Market cap
- $30.84B
- $415.1M
- 1M return
- -1.96%
- -
- 1Y return
- +31.19%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 16
- 0
- Recent ratings
- 25
- 5
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
SeaSpine Holdings Corporation
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
Latest NTRA
- CEO AND PRESIDENT Chapman Steven Leonard sold $9,089,776 worth of shares (41,124 units at $221.03) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 108,743 units (SEC Form 4)
- Natera Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
- PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $655,295 worth of shares (3,000 units at $218.43) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 137,643 units (SEC Form 4)
- Director Rubin Eric H was granted 2,124 shares, increasing direct ownership by 42,480% to 2,129 units (SEC Form 4)
- Director Botha Roelof sold $17,184,092 worth of shares (78,000 units at $220.31) (SEC Form 4)
- Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors
- Wolfe Research resumed coverage on Natera with a new price target
- SEC Form 144 filed by Natera Inc.
- Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Latest SPNE
- SEC Form CT ORDER filed by SeaSpine Holdings Corporation
- SEC Form SC 13G/A filed by SeaSpine Holdings Corporation (Amendment)
- SEC Form 15-12G filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form EFFECT filed by SeaSpine Holdings Corporation
- SEC Form 4: Stephenson Kirtley C. returned 138,340 shares to the company, closing all direct ownership in the company
- SEC Form 4: Steinway Angela returned 23,725 shares to the company, closing all direct ownership in the company
- SEC Form 4: Maniar Shweta returned 23,993 shares to the company, closing all direct ownership in the company
- SEC Form 4: Gaeta Renee returned 36,056 shares to the company, closing all direct ownership in the company